Nanomed
Empowering healthcare with advanced graphene biosensors for accelerated life science and drug discovery research.
Empowering healthcare with advanced graphene biosensors for accelerated life science and drug discovery research.
Nanomed is a biotechnology company founded in 2013 and based in San Diego, California. Specializing in advanced graphene biosensor products, Nanomed is committed to empowering healthcare through accelerated life science and drug discovery research. Their innovative electrical assay, based on proprietary Field Effect Biosensing (FEB) technology, enables label-free, highly sensitive binding studies of small molecules to proteins, offering advantages such as a wide dynamic range and minimal signal interference. Recently, the company secured Series A investment from SandHill Angels on October 23, 2020. As the foremost mass-manufacturer of advanced graphene biosensors, Nanomed aims to revolutionize the healthcare industry by introducing new products supporting life science and drug discovery research.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 1 |
|
23 Oct 2020 |
| Series A | Unknown | 1 |
|
01 Jan 2019 |
| Venture Round | Unknown | 1 |
|
21 Jul 2017 |
| Venture Round | Unknown | 1 |
|
17 Apr 2017 |
| Venture Round | Unknown | 1 |
|
14 Dec 2016 |
No recent news or press coverage available for Nanomed.
We care about your data, and we'd love to use cookies make your experience better.
